DCTH Delcath stock news
On September 7, 2026, Delcath Systems Inc. (Nasdaq: DCTH) announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J--code for the HEPZATO KIT, effective October 1, 2026. This regulatory milestone is expected to significantly streamline the reimbursement process for healthcare providers and facilitate broader patient access to the company's liver--directed therapy for metastatic uveal melanoma. The transition to a permanent J--code is a critical component of the company's commercial strategy to optimize revenue cycle management for its expanding network of treatment centers.